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Susan Tower, MD,5 and Devin L. Brown, MD2
Objective: To examine the association between sleep-disordered breathing and stroke outcomes, and determine the
contribution of sleep-disordered breathing to outcome disparities in Mexican Americans.
Methods: Ischemic stroke patients (n = 995), identified from the population-based Brain Attack Surveillance in Corpus
Christi Project (2010–2015), were offered participation in a sleep-disordered breathing study including a home sleep apnea
test (ApneaLink Plus). Sleep-disordered breathing (respiratory event index ≥10) was determined soon after stroke. Neuro-
logic, functional, cognitive, and quality of life outcomes were assessed at 90 days poststroke. Regression models were used
to assess associations between sleep-disordered breathing and outcomes, adjusted for sociodemographics, prestroke func-
tion and cognition, health-risk behaviors, stroke severity, and vascular risk factors.
Results: Median age was 67 years (interquartile range [IQR] = 59–78); 62.1% were Mexican American. Median respira-
tory event index was 14 (IQR = 6–25); 62.8% had sleep-disordered breathing. Sleep-disordered breathing was associated
with worse functional outcome (mean difference in activities of daily living/instrumental activities of daily living score = 0.15,
95% confidence interval [CI] = 0.01–0.28) and cognitive outcome (mean difference in modified Mini-Mental State Examina-
tion = −2.66, 95% CI = −4.85 to −0.47) but not neurologic or quality of life outcomes. Sleep-disordered breathing
accounted for 9 to 10% of ethnic differences in functional and cognitive outcome and was associated with cognitive out-
come more strongly for Mexican Americans (β = −3.97, 95% CI = −6.63 to −1.31) than non-Hispanic whites (β = −0.40,
95% CI = −4.18 to 3.39, p-interaction = 0.15).
Interpretation: Sleep-disordered breathing is associated with worse functional and cognitive function at 90 days post-
stroke. These outcomes are reasonable endpoints for future trials of sleep-disordered breathing treatment in stroke. If
effective, sleep-disordered breathing treatment may somewhat lessen ethnic stroke outcome disparities.
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Stroke is the fifth leading cause of death in the UnitedStates.1 Stroke mortality rates have declined substan-
tially over the past 4 decades.2 Decreasing stroke mortality
in combination with aging of the US population will
result in an increase in the number of people living with
stroke-related disability. Projections suggest that by 2050 the
number of stroke events will reach 1.3 million, with the
greatest increases in minority populations, who have higher
stroke rates, worse stroke outcomes, and greater projected
population growth.3 The increase in the number of disabled
stroke survivors will pose significant challenges to the US
health care system, pointing to the urgent need for new
interventions to improve stroke recovery.
Sleep-disordered breathing (SDB), a treatable condi-
tion, is highly prevalent in ischemic stroke patients.4 The
limited epidemiologic data on the association between SDB
and stroke outcomes have come primarily from small, single-
hospital or rehabilitation-based studies.5–15 Patients in inpa-
tient rehabilitation are a select group of moderately severe
stroke patients who are medically stable enough to participate
in more lengthy therapy sessions. Thus, stroke patients with
more adverse outcomes, and possibly more severe SDB, are
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excluded, introducing possible selection bias. Data from
larger, population-based studies that represent the broader
stroke population are lacking. Moreover, information is lim-
ited on the impact of SDB on stroke outcomes beyond dis-
ability, such as quality of life (QOL) and cognition.
Small randomized clinical trials (RCTs) have dem-
onstrated that treatment of SDB with continuous positive
airway pressure (CPAP) in select groups of stroke/transient
ischemic attack (TIA) patients may improve functional out-
come, cognitive outcome, neurologic recovery, and depressive
symptoms, although results have not been conclusive.16–25 If
treatment with CPAP is shown to improve stroke outcomes in
a larger, adequately powered clinical trial, treatment of SDB
may be a viable, cost-efficient intervention strategy to improve
stroke recovery. Observational data on the association of SDB
with a variety of stroke outcomes could inform the most
appropriate endpoints for future recovery trials of SDB treat-
ment in stroke patients.
Minority populations, including Mexican Americans
(MAs), in comparison to non-Hispanic whites (NHWs),
have worse poststroke outcomes and a higher prevalence
of post–ischemic stroke SDB.4,26 If SDB is associated with
worse outcomes, then SDB may contribute to ethnic stroke
outcome disparities and through its treatment offer a novel
opportunity to reduce disparities. In addition, the association
between SDB and stroke outcomes may vary by ethnicity due
to ethnic differences in the pathophysiology of SDB. Data on
the association between SDB and stroke outcomes from
diverse populations, who bear a greater stroke burden, are
lacking.
The objectives of this study therefore were 2-fold: (1) to
examine the association between SDB and 90-day stroke out-
comes, and (2) to understand the contribution of SDB to
worse stroke outcomes in MAs compared with NHWs.
Patients and Methods
Study Setting
The ongoing Brain Attack Surveillance in Corpus Christi
(BASIC) Project takes place in Nueces County, Texas,
which had a population of 361,350 in 2016, the majority
being US-born MAs.27 Nueces County is similar to other
US communities with high concentrations of US-born
MAs with respect to sociodemographic factors linked to
stroke, suggesting results will be generalizable to the non-
immigrant US MA population.28 The county has 7 acute
care hospitals, with other major referral centers ~150 miles
away, affording complete case capture for acute stroke.
Stroke Ascertainment
Detailed methods of the BASIC Project have been publi-
shed.29 Briefly, active and passive surveillance methods are
used to identify possible strokes at all hospitals in the
study area. Active surveillance entails routinely screening
hospital admission logs for screening terms suggestive of
stroke as well as routinely canvassing hospital floors and
intensive care units for in-hospital strokes. Passive surveil-
lance entails review of discharge diagnosis codes for stroke.
All possible strokes are validated by stroke fellowship-trained
physicians blinded to ethnicity and age. This analysis was
focused on ischemic strokes defined using a standard clinical
definition.30 Only patients who were MAs or NHWs were
included due to the small numbers for other racial–ethnic
groups.
Sleep-Disordered Breathing
Individuals are approached soon after stroke for participa-
tion in BASIC, which includes a baseline interview and an
outcome interview at ~90 days after stroke. Eligibility
includes age ≥45 years, residence in Nueces County for
≥6 months per year, and stroke not as a result of trauma.
Individuals are eligible for the SDB portion of the study if
stroke onset is within 30 days if it is identified through active
surveillance, and within 45 days if it is identified through pas-
sive surveillance. Exclusion criteria include current pregnancy
or use of oxygen or positive pressure ventilation. Eligible indi-
viduals are offered participation in an SDB study that includes
a home sleep apnea test (HSAT) with the well-validated
ApneaLink Plus.31 A recent study supported the accuracy of
poststroke SDB assessment with an HSAT.32 Trained study
coordinators apply the device in the hospital or the subjects’
homes. Raw data are downloaded for processing by the
ApneaLink software. Default settings for the software are used
for automated scoring, with edits to start and stop times and
artifacts by a registered polysomnographic technologist. As pre-
viously detailed,33 the technologist also adjusts poor quality
data, reactivates some data for scoring through sensitivity
adjustment, and reclassifies a small number of apneic events
not scored in a manner consistent with guidelines. Definitions
for apneas and hypopneas were as follows: apneas, a decrease in
nasal pressure of ≥80% from baseline for ≥10 seconds;
hypopneas, a decrease in nasal pressure of ≥30% compared to
baseline, lasting ≥10 seconds and associated with a ≥4% oxy-
gen desaturation. In the presence of missing oximetry data,
hypopneas were defined as a reduction in nasal pressure of
≥50% for ≥10 seconds. A respiratory event index (REI), the
sum of apneas plus hypopneas per hour of recording, was cal-
culated. SDB was identified by an REI ≥10. Although the
International Classification of Sleep Disorders defines signifi-
cant obstructive sleep apnea by an apnea–hypopnea index or
REI ≥5, we chose the higher threshold (and a focus on “signifi-
cant SDB”) a priori in view of the high sensitivity and specific-
ity for the ApneaLink at this cutpoint, and our evidence that
nearly all poststroke patients might qualify for SDB if the lower
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threshold were used.4,31 ApneaLink Plus results were provided
to subjects after their 90-day outcome assessment.
Stroke Outcomes
In-person interviews are conducted with subjects or their
proxy (if subject is unable to communicate) at ~90 days
following stroke. Neurologic outcome measured by the
National Institutes of Health Stroke Scale (NIHSS) is
assessed by certified study coordinators. Functional out-
come is measured with 7 self-reported activities of daily
living (ADL) and 15 instrumental activities of daily living
(IADL). Subjects respond to their level of difficulty per-
forming each ADL/IADL item with a Likert scale ranging
from 1 (no difficulty) to 4 (can only do with help). The
items are averaged to create a functional outcome score rang-
ing from 1 to 4, with higher scores representing worse func-
tion. Cognitive outcome is measured with the modified
Mini-Mental State Examination (3MSE). The 3MSE ranges
from 0 to 100, with higher scores representing better cogni-
tive function. Subjects are administered a series of questions
to assess language dysfunction and ability to participate in
cognitive testing prior to administration. QOL is measured
with the short form Stroke Specific Quality of Life (SS-
QOL) scale, which has been validated in our population.34
The SS-QOL ranges from 1 to 5, with higher scores rep-
resenting better QOL. All-cause mortality is ascertained
through records from the Texas Department of State Health
Services and next of kin reports.
Covariates
Potential confounders included sociodemographic and
prestroke characteristics from baseline interviews and stroke
characteristics and vascular risk factors from medical records.
Sociodemographic characteristics were race–ethnicity, age, sex,
education, andmarital status. Prestroke characteristics included
cognitive impairment measured by the Informant Question-
naire on Cognitive Decline in the Elderly (IQCODE; catego-
rized as normal cognitive function, cognitive impairment
without dementia, dementia),35 functional disability measured
by the modified Rankin Scale (mRS; categorized as no,
slight/moderate, severe), and health-risk behaviors (current
smoking, alcohol use in 4 categories). Stroke characteristics
included initial stroke severity measured by the NIHSS and
intravenous tissue plasminogen activator (tPA) use. Vascular
risk factors included body mass index, atrial fibrillation, diabe-
tes, coronary artery disease, history of stroke/TIA, hyperten-
sion, and hyperlipidemia.
BASIC was approved by the institutional review
boards at the University of Michigan and the local hospi-
tal systems. All patients or their surrogates provided writ-
ten informed consent.
Study Participants
Sample construction and attrition are presented in the Figure
1. Briefly, there were 2,289 ischemic stroke patients identified
(August 23, 2010 to December 29, 2015). For patients who
experienced >1 event during the study period, the first event
with SDB testing was retained. Among the 2,289 patients,
337 patients who died prior to 90 days and 14 patients who
had incomplete medical record data were excluded. Among the
remaining 1,938 patients, 1,280 MA and NHW patients par-
ticipated in the baseline interview, of whom 995 had a 90-day
outcome interview. Of the 995 with outcome data, 623 had
SDB measured. Missing values for SDB (n = 372), IQCODE
(n = 119), and other covariates were multiply imputed using a
regression predictive matching algorithm. Outcome models for
the primary analysis were fit in the 995 patients. Data for
patients who remained alive but did not participate in the base-
line interview (n = 337), and those who participated in a base-
line but not outcome interview (n = 285), were used in
analysis to account for any potential differential attrition using
inverse probability weighting but were not included in the pri-
mary analysis. Descriptive analyses comparing those who did
and did not participate in the baseline interview and those who
did and did not participate in the sleep study are presented in
Supplementary Tables 1 and 2.
Statistical Analysis
Differences in sample characteristics by participation status
were examined using chi-squared and t tests. Logistic
regression models were used to derive inverse probability
weights (IPWs) to account for differential participation at
baseline, and attrition from baseline to the 90-day outcome
assessment.36 Weights were calculated as the inverse of the
probability of participation at baseline (weight 1) and the
inverse probability of participation in outcome given base-
line participation (weight 2). Each weight was stabilized by
multiplying it by the average probability of participation at
each stage, and trimmed at the 1st and 99th percentiles of
the distribution to minimize the impact of extreme weights.
The 2 weights were multiplied together to produce a final
weight to be used in regression models.
Weighted regression models were used to investigate
the adjusted associations between SDB and 90-day out-
comes. As cognitive, functional, and QOL scores exhibit
truncated distributions, we used Tobit regression for these out-
comes. Robust regression was used to model log-transformed
NIHSS measured at 90 days to accommodate the skewed dis-
tribution of this outcome. We estimated separate models for
each outcome, adjusted for sociodemographics (age, sex, eth-
nicity, education, marital status), prestroke functional disability
(mRS) and cognitive impairment (IQCODE), health-risk
behaviors (alcohol intake and smoking), initial NIHSS, treat-
ment with tPA, and vascular risk factors (body mass index,
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atrial fibrillation, coronary artery disease, diabetes, hyperten-
sion, high cholesterol, history of stroke/TIA). Body mass index
was modeled continuously including a quadratic term to
accommodate lack of linearity.
To examine the role of SDB in ethnic disparities, we
investigated both the potential for SDB to confound the
ethnicity–outcome associations and differences in SDB–
outcome associations by ethnicity. Although it is possible that
SDB serves as a mediator between ethnicity and stroke out-
comes through a genetic mechanism,37 we hypothesize that
the more likely scenario is an association between ethnicity
and SDB due to environmental and lifestyle factors. Thus,
we focus our analysis, and interpretation of the role of SDB
in ethnic stroke outcome disparities, on confounding versus
mediation. For confounding, we estimated ethnic differences
with and without inclusion of SDB in the confounder-
adjusted models. For effect modification, we included interac-
tion terms between ethnicity and SDB, and between ethnicity
and all other covariates. This strategy approximates stratified
models by ethnicity, but has the advantage of formally testing
for differences in the association of SDB and outcome by eth-
nicity. A priori, a p value of 0.15 was set to determine pres-
ence of effect modification.38 We report ethnic-specific
associations between SDB and outcomes from stratified
models for ease of interpretation.
To estimate the proportion of the outcomes in the stroke
population attributable to SDB, we calculated ethnic-specific
estimates of population attributable risk percentage (PAR%).
This analysis was limited to cognitive outcome, as this outcome
had a significant association with SDB in MAs. For these cal-
culations, a separate fully adjusted logistic regression model was
run to estimate the relative risk for poor outcome associated
with SDB, with poor outcome defined as 3MSE < 78.39
Results
Tables 1 and 2 includes participant characteristics in the com-
plete data (n = 995) as well as in the imputed data. Median
age was 67 years (interquartile range [IQR] = 59–78), 62.1%
were MAs, and 51.7% were women. Median REI was
FIGURE 1: Sample construction and attrition. 3MSE = modified Mini-Mental State Examination; ADL = activities of daily living;
AHI = apnea–hypopnea index; IADL = instrumental activities of daily living; IQCODE = Informant Questionnaire on Cognitive
Decline in the Elderly; MA = Mexican American; MR_Other = missing race_ethnicity; MRS = modified Rankin Scale; NHW = non-
Hispanic white; NIHSS = National Institutes of Health Stroke Scale; SS-QOL = Stroke Specific Quality of Life.
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TABLE 1. Baseline Characteristics for Complete and Imputed Data
Variable n
Complete Data
Median (IQR) or %
Imputed Data, n = 995,
Median (IQR) or %
Sociodemographic characteristics
Mexican American 995 62.1 62.1
Female 995 51.7 51.7
Age 995 67.0 (59.0–78.0) 67.0 (59.0–78.0)
Education
College 991 37.8 37.7
High school 991 28.7 28.5
Less than high school 991 33.5 33.8
Marital status 994
Never married 7.3 7.3
Married or living with someone 47.7 47.6
Widowed 23.6 23.6
Divorced/separated 21.3 21.3
Prestroke characteristics
IQCode, range = 1–5 876
≤3 49.2 49.6
>3–4 43.4 43.0
>4 7.42 7.4
mRS, range = 0–5 978
0–1 42.3 42.0
2–3 45.8 45.9
≥4 11.9 12.1
Current smoker 992 22.1 22.1
Alcohol intake per week 995
Does not drink 22.6 22.6
<1 drink 46.5 46.5
1–14 drinks 24.9 24.9
15 or more drinks 5.9 5.9
Stroke characteristics
NIHSS 991 3.0 (1.0–7.0) 3.0 (1.0–7.0)
Treatment with tPA 995 14.3 14.3
Vascular risk factors
Body mass index 995 28.3 (24.9–32.8) 28.3 (24.9–32.8)
Atrial fibrillation 993 13.6 13.6
Coronary artery disease 993 29.6 29.6
Diabetes 995 47.4 47.4
Hypertension 995 80.7 80.7
High cholesterol 994 51.6 51.6
History of stroke/TIA 994 28.1 28.0
IQCode = Informant Questionnaire on Cognitive Decline in the Elderly; IQR = interquartile range; mRS = modified Rankin Scale; NIHSS = National
Institutes of Health Stroke Scale; TIA = transient ischemic attack; tPA = tissue plasminogen activator.
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14 (IQR = 6-25), and 62.8% had SDB (REI ≥10). Median
central apnea index was 0 (IQR = 0–2). Participants, on average,
had favorable 90-day outcomes. Median ADL/IADL score
(range = 1-4, higher scores are worse) was 2.2 (IQR = 1.4–3.3),
median NIHSS was 2.0 (IQR = 0–5.0), median 3MSE score
was 88 (IQR = 78–94), and median SS-QOL (range = 1–5,
higher scores are worse) was 3.3 (IQR = 2.3–4.3).
SDB and 90-Day Stroke Outcomes
SDB was significantly associated with worse functional
and cognitive outcomes after adjustment for confounders
(Table 3). Subjects with SDB scored on average 0.15 points
higher on the ADL/IADL score (β = 0.15, 95% confidence
interval [CI] = 0.01–0.28) and 2.66 points lower on the
3MSE than those without SDB (β = −2.66, 95% CI = −4.85
to −0.47). SDB was not associated with neurologic or QOL
outcomes at 90 days.
Ethnicity, SDB, and 90-Day Stroke Outcomes
Prevalence of SDB was 69.2% in MAs and 53.5%
NHWs.MA ethnicity was adversely associated with all 4 stroke
outcomes after adjustment (Table 4). After including SDB in
the models, the ethnicity association was attenuated by ~9%
for functional outcome, 10% for cognitive outcome, 6% for
QOL, and 4% for neurologic outcome. Formal tests for effect
modification of the SDB–stroke outcome associations by eth-
nicity suggested possible ethnic differences for cognitive out-
come and QOL (p for interaction ≤0.15; Table 5). For
cognitive outcome, the association with SDB was stronger and
reached statistical significance for MAs (β = −3.97, 95%
CI =−6.63 to−1.31) as opposed toNHWs, among whom no
association was observed (β = −0.40, 95% CI = −4.18 to
3.39). PAR% for SDB and cognitive outcomes suggest that, if
SDB is causally related to cognitive outcome, ~8% of poor
poststroke cognitive outcomes in MAs could be eliminated if
TABLE 2. Sleep and Outcome Characteristics for Complete and Imputed Data
Variable n
Complete Data
Median (IQR)
Imputed Data, n = 995,
Median (IQR)
Sleep measures
REI 623 14.0 (6.0–25.0) 13.0 (6.0–26.0)
SDB, REI ≥10 623 62.8 62.7
90-day stroke outcomes
ADL/IADL score, range = 1–4 974 2.2 (1.4–3.3) 2.2 (1.4–3.3)
NIHSS, range 1–42 948 2.0 (0.0–5.0) 2.0 (0.0–5.0)
3MSE 770 88.0 (78.0–94.0) 87.0 (73.0–94.0)
SS-QOL 990 3.3 (2.3–4.3) 3.3 (2.3–4.3)
3MSE = modified Mini-Mental State Examination; ADL = activities of daily living; IADL = instrumental activities of daily living; IQR = interquartile
range; NIHSS = National Institutes of Health Stroke Scale; REI = respiratory event index; SDB = sleep-disordered breathing; SS-QOL = Stroke Spe-
cific Quality of Life.
TABLE 3. Adjusteda Associations between Sleep-Disordered Breathing and 90-Day Stroke Outcomes
ADL/IADL,
Range = 1–4, Mean
Difference (95% CI)
3MSE, Range = 0–100,
Mean Difference (95% CI)
NIHSS, Range = 1–42,
Relative Differencea
(95% CI)
SS-QOL,
Range = 1–5, Mean
Difference (95% CI)
SDB, REI ≥10,
yes vs no
0.15 (0.01–0.28) −2.66 (−4.85 to −0.47) 1.11 (0.94–1.31) −0.09 (−0.23 to 0.06)
aModels are adjusted for sociodemographics (age, sex, ethnicity, education, marital status), prestroke functional disability (modified Rankin Scale) and
cognitive impairment (Informant Questionnaire on Cognitive Decline in the Elderly), health-risk behaviors (alcohol intake, smoking), initial NIHSS,
treatment with tissue plasminogen activator, and vascular risk factors (body mass index, atrial fibrillation, coronary artery disease, diabetes, hyperten-
sion, high cholesterol, history of stroke/transient ischemic attack).
3MSE = modified Mini-Mental State Examination; ADL = activities of daily living; CI = confidence interval; IADL = instrumental activities of daily
living; NIHSS = National Institutes of Health Stroke Scale; REI = respiratory event index; SDB = sleep-disordered breathing; SS-QOL = Stroke Spe-
cific Quality of Life.
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SDB were eliminated. For QOL, SDB showed no association
in MAs (β = −0.17, 95% CI = −0.38 to 0.03) or NHWs
(β = 0.11, 95%CI =−0.14 to 0.36).
Discussion
Results from this large and diverse population-based sample of
ischemic stroke patients show that significant SDB shortly
after the event is associated with worse functional and cogni-
tive function at 90 days poststroke. This association persisted
despite comprehensive adjustment for confounding factors,
and for potential selection bias. These results raise the hypoth-
esis that SDB treatment may improve stroke recovery in these
critical outcome domains. If SDB treatment is proven to be
effective, this therapy could have a substantial impact on the
growing number of disabled stroke survivors, as the majority
have SDB.4
Pilot RCTs have evaluated the effect of CPAP on func-
tional and cognitive outcomes, with mixed results.6,16,18,20–24
TABLE 4. Adjusteda Associations Between Ethnicity and Ninety-day Stroke Outcomes Before and After
Adjustment for Sleep-Disordered Breathing
Model
ADL/IADL,
Range = 1–4,
Mean Difference
(95% CI)
3MSE,
Range = 0–100,
Mean Difference
(95% CI)
NIHSS,
Range = 1–42,
Mean Difference
(95% CI)
SS-QOL,
Range = 1–5,
Mean Difference
(95% CI)
Ethnicity, MA vs NHW,
without SDB in model
0.20 (0.09–0.31) −3.22 (−5.50 to −0.94) 1.34 (1.16–1.55) −0.17 (−0.31 to −0.03)
Ethnicity, MA vs NHW,
with SDB in model
0.18 (0.07–0.30) −2.90 (−5.16 to −0.64) 1.32 (1.14–1.53) −0.16 (−0.30 to −0.02)
Change in ethnicity
association comparing
models without
and with SDB
8.6% 9.9% 4.3% 6.0%
aModels are adjusted for sociodemographics (age, sex, ethnicity, education, marital status), prestroke functional disability (modified Rankin Scale) and
cognitive impairment (Informant Questionnaire on Cognitive Decline in the Elderly), health-risk behaviors (alcohol intake, smoking), initial NIHSS,
treatment with tissue plasminogen activator, and vascular risk factors (body mass index, atrial fibrillation, coronary artery disease, diabetes, hyperten-
sion, high cholesterol, history of stroke/transient ischemic attack).
3MSE = modified Mini-Mental State Examination; ADL = activities of daily living; CI = confidence interval; IADL = instrumental activities of daily
living; MA = Mexican American; NHW = non-Hispanic white; NIHSS = National Institutes of Health Stroke Scale; SDB = sleep-disordered breath-
ing; SS-QOL = Stroke Specific Quality of Life.
TABLE 5. Adjusteda Ethnic-Specific Associations between Sleep-Disordered Breathing and 90-Day Stroke
Outcomes
ADL/IADL,
Range = 1–4, Mean
Difference (95% CI)
3MSE, Range = 0–100,
Mean Difference
(95% CI)
NIHSS, Range = 1–42,
Mean Difference
(95% CI)
SS-QOL,
Range = 1–5, Mean
Difference (95% CI)
NHW 0.10 (−0.10 to 0.29) −0.40 (−4.18 to 3.39) 0.99 (0.78–1.25) 0.11 (−0.14 to 0.36)
MA 0.16 (−0.03 to 0.35) −3.97 (−6.63 to −1.31) 1.16 (0.92–1.47) −0.17 (−0.38 to 0.03)
Ethnicity × SDB
interaction, p
0.65 0.15 0.33 0.11
aModels are adjusted for sociodemographics (age, sex, ethnicity, education, marital status), prestroke functional disability (modified Rankin Scale) and
cognitive impairment (Informant Questionnaire on Cognitive Decline in the Elderly), health-risk behaviors (alcohol intake, smoking), initial NIHSS,
treatment with tissue plasminogen activator, and vascular risk factors (body mass index, atrial fibrillation, coronary artery disease, diabetes, hyperten-
sion, high cholesterol, history of stroke/transient ischemic attack), as well as the interactions between ethnicity and these covariates.
3MSE = modified Mini-Mental State Examination; ADL = activities of daily living; CI = confidence interval; IADL = instrumental activities of daily
living; MA = Mexican American; NHW = non-Hispanic white; NIHSS = National Institutes of Health Stroke Scale; SDB = sleep-disordered breath-
ing; SS-QOL = Stroke Specific Quality of Life.
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The majority of trials were conducted in stroke rehabilitation
units or a limited number of hospitals, with sample sizes rang-
ing from 30 to 252. Our results now suggest that functional
and cognitive outcomes are reasonable targets for larger, ade-
quately powered trials of the effectiveness of CPAP in improv-
ing stroke outcomes. Functional and cognitive outcomes as
opposed to QOL and NIHSS appear more likely to show
benefit. An ongoing, multicenter phase 3 clinical trial (Sleep
for Stroke Management and Recovery Trial, or Sleep
SMART) will test whether treatment of SDB with CPAP
after an ischemic stroke or TIA improves 90-day outcomes.
With functional status as the primary outcome, and cognition
as a secondary endpoint, Sleep SMART could provide defini-
tive evidence as to the potential for SDB treatment to
improve stroke outcomes.
Our results suggest that SDB contributes to worse
outcomes in MAs compared with NHWs via 2 pathways.
First, as described above, we demonstrated that SDB was
associated with worse functional and cognitive outcomes.
As SDB is also more prevalent in MAs,4 SDB appears to
help explain the association between ethnicity and func-
tional and cognitive outcomes. Our results suggest that
9 to 10% of the ethnic disparity in these outcomes is
explained by SDB. Second, our results suggested a stronger
association between SDB and worse cognitive outcome in
MAs than in NHWs. We approximated that 8% of poor
cognitive outcomes could be eliminated in the MA stroke
population if SDB were eliminated, a conservative estimate
given the definition used to define poor outcome. Therefore,
effective treatment for SDB holds some promise for reduc-
ing poor functional and cognitive outcomes in the growing
number of MA stroke survivors, although our estimates sug-
gest that additional interventions will also be needed to
reduce outcome disparities.
The suggested stronger association between SDB and
cognitive outcome in MAs compared with NHWs raises
the question of potential mechanisms. The finding is not
driven by ethnic differences in severity of SDB or in treat-
ment of SDB poststroke based on our previous work.4,40
Alternatively, downstream consequences of SDB may vary
by ethnicity. For example, MAs may experience lower blood
oxygen levels during sleep, greater reductions in sleep effi-
ciency, greater reductions in slow wave or rapid eye move-
ment sleep, or greater reduction in spindle activity, which
may translate into poorer cognitive outcome.41–44 Another
possibility is synergistic effects of SDB and other risk factors
for poor stroke outcome. For example, individuals with dia-
betes and low sleep efficiency have poorer cognitive function
than those with higher sleep efficiency.45 Synergistic effects
between SDB and obesity on cognitive function have also
been observed.46 MAs with stroke have higher prevalence of
both diabetes and obesity than NHWs.26 More research is
needed to understand mechanisms linking SDB to cognitive
outcomes in MAs. Use of full polysomnography—even if
unattended, to make it a feasible option just after stroke—
might allow greater characterization of poststroke SDB.
Such research would speak to the potential for existing SDB
treatments to improve cognitive outcome in MAs with
stroke, or possibly indicate whether novel treatment targets
are needed. Our finding of ethnic differences in the SDB–
cognitive outcome association also suggests the need for
future studies, and perhaps clinical trials, to evaluate rela-
tionships within groups defined by race–ethnicity.
This study is the first large, population-based study of
SDB and QOL in stroke patients. Use of patient-reported
outcomes, such as QOL, in stroke research is growing with
the recognition that measuring patient-perceived health sta-
tus is critical to improvement of patient outcomes and
involvement of patients more directly in stroke care deci-
sions.47 Although we found no overall association between
SDB just after stroke and QOL at 90 days, an association
was suggested in MAs, consistent with the observed adverse
effects of SDB on the other stroke outcomes in this ethnic
group. Literature on the association of SDB and QOL in
stroke patients is limited. One small study of 22 stroke
patients showed a correlation between impaired sleep quality
and QOL, which is consistent with our findings.48 Outside
of stroke, SDB is associated with poorer QOL, and treat-
ment of moderate to severe SDB with CPAP improves
QOL.49,50 Additional research is needed to understand the
impact of SDB on a broader range of patient-reported out-
comes critical to healthy living, such as sexual function,
work, and social engagement, among others.
There are limitations that warrant discussion. Given
the logistical challenges with full polysomnography in stroke
patients, we used an HSAT. The device used has been well
validated when using the 4% desaturation criterion to define
hypopneas, suggesting minimal misclassification of SDB.
Our statistical methods included use of imputation and
IPWs to minimize selection bias, a strength of the study.
However, there was a considerable degree of missing data
and there may be patients who were eligible for the study
but not represented in the sample and therefore cannot be
accounted for by IPW methods. For these reasons, some
caution in the interpretation of our results is advised.
Although our sample size was large, the study may have been
underpowered to detect effect modification. Furthermore,
although our consideration of effect modification of the
SDB–outcome associations by ethnicity was justified based
on our a priori hypothesis of potential differences in patho-
physiology of SDB by ethnicity, our results regarding the
presence of effect modification should be interpreted with
caution and require replication in other studies. Given that
our intent was to assess causal associations, we adjusted for
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all possible confounders. It is possible that some factors, such
as hypertension and diabetes, are on the causal pathway, and
therefore we may have overadjusted. However, our previous
work suggests that these factors are not associated with func-
tional and cognitive outcomes, arguing against the media-
tion hypothesis.26 Finally, we a priori hypothesized that
SDB confounds the association between ethnicity and stroke
outcomes. It is also possible that SDB serves as a mediator of
the ethnicity–stroke outcome associations, and this warrants
further investigation.
Summary
Significant SDB just after stroke shows associations with
worse functional and cognitive outcomes at 90 days. The
potential for an underlying causal effect raises the possibility
that identification and treatment of SDB after stroke could
have substantial impact on recovery. Functional and cogni-
tive outcomes appear to be reasonable endpoints for RCTs
of SDB treatments in stroke patients. Moreover, SDB may
contribute to these outcomes disproportionately in MAs
compared with NHWs, suggesting that effective poststroke
SDB treatment may lessen ethnic stroke disparities.
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